

Ref: FOI/GS/ID 8377

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

02 August 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Nivolumab.

You asked:

Q1. In the last 3 months, how many patients have been initiated on the following agents for the treatment of melanoma?*

- a. Ipilimumab (monotherapy)*
- b. Nivolumab (monotherapy)*
- c. Nivolumab AND Ipilimumab (combination)*
- d. Pembrolizumab*
- e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
- f. Other active systemic anti-cancer therapy*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q2. In the last 3 months, how many patients have been initiated on the following agents for the treatment of renal cell carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. In the past 3 months, how many patients have been initiated on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:*

- a. Nivolumab monotherapy or in combination with Ipilimumab*

b. *Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)*

c. *Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Trust response:

1.

a. 0

b. 0

c. 10

d. 19

e. 3

f. 0

2.

a. 4

b. 1

c. 0

d. 1

3.

a. 0

b. 0

c. 1